YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma i

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

References

1. Eggermont A and Robert C. New drugs in melanoma: it's a whole new world. European J Cancer 2011; 47:2150-57

2. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23

3. European Commission - Community Register of Medicinal Products. Updated October 2013. Available at: http://ec.europa.eu/health/documents/community-register/html.... Last accessed November 2013

4. Chin L et al. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.

5. YERVOY Summary of Product Characteristics 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?c... . Last accessed November 2013

6. Robert C et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 2011; 364:2517-26

7. Margolin K, Wong SL, Penrod JR, et al. Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review. Presented at: The European Cancer Congress 2013; September 27 - October 1; Amsterdam, The Netherlands (P488)

8. Patt D, Wong SL, Juday T, et al. community-based, real-world, study of treatment-naïve advanced melanoma (AM) patients treated with 3mg/kg ipilimumab (IPI) in the United States. Presented at: The European Cancer Congress 2013; September 27 - October 1; Amsterdam, The Netherlands (P497)

9. Skin Cancer Foundation. What is melanoma? Available at http://www.skincancer.org/Melanoma. Last accessed November 2013

10. National Cancer Institute. Fact Sheet. Metastatic Cancer. Available at: http://www.cancer.gov/cancertopics/factsheet/Sites-Types/met... Last accessed October 2013

11. American Cancer Society. What is metastatic cancer? Available at: http://www.cancer.org/treatment/understa... . Last accessed November 2013

12. Garbe C et al. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9.

13. Markovic SN et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82:364-38014. American Cancer Society. Melanoma skin cancer. Can melanoma be found early? Available at: http://www.cancer.org/cancer/skincancer-melanoma/detailedgui... . Last accessed November 2013

CONTACT: Media Contact: Elzbieta Zawislak, +48-608-55-55-89,elzbieta.zawislak@bms.com